Service Rendered Directly To Third Parties was Jrsis Health Care’s largest revenue line in fiscal 2023, bringing in $1.39M of $3.46M (40%).
| Related Party, Type | FY 2022 | FY 2023 |
|---|---|---|
| Goods Sold To Related Parties | $1.34M | $773.50K |
| Service Rendered To Related Parties | — | $959.26K |
| Service Rendered Directly To Third Parties | $250.13K | $1.39M |
| Goods Sold Directly To Third Parties | $133.60K | $336.61K |
| Total | $1.72M | $3.46M |
Jrsis Health Care brought in $3.46M from its four revenue lines in fiscal 2023, the year ended December 31, 2023. Jrsis Health Care regrouped these revenue lines after fiscal 2022, so the total does not compare directly with that year's $1.72M. Service Rendered Directly To Third Parties was the largest at $1.39M (40.2%), ahead of Service Rendered To Related Parties at $959.26K (27.7%) and Goods Sold To Related Parties at $773.50K (22.3%). The remaining revenue line, Goods Sold Directly To Third Parties, brought in $336.61K.
Compared with fiscal 2022, Service Rendered Directly To Third Parties grew fastest, up 456.7% to $1.39M, while Goods Sold To Related Parties fell the most, down 42.1% to $773.50K.
Jrsis Health Care began breaking out Service Rendered To Related Parties in fiscal 2023, when it brought in $959.26K.
Patient Services was Jrsis Health Care’s largest revenue line in fiscal 2021, bringing in $32.89M of $44.39M (74%).
| Health Care Organization Revenues | FY 2017 | FY 2018 | FY 2020 | FY 2021 |
|---|---|---|---|---|
| Patient Services | — | $26.31M | $32.89M | |
| Pharmaceuticals | — | $9.40M | $11.51M | |
| Western Medicine | — | — | — | |
| Western Pharmaceuticals | $8.61M | — | — | |
| Medical Consulting | $8.72M | — | — | |
| Medical Treatment | $8.11M | — | — | |
| Chinese Medicine | $1.75M | — | — | |
| Herbal Medicine | $816.31K | — | — | |
| Others | $392.77K | — | — | |
| Total | $28.40M | $35.71M | $44.39M |
Jrsis Health Care brought in $44.39M from its two revenue lines in fiscal 2021, the year ended December 31, 2021. That was up 24.3% from $35.71M in fiscal 2020. Patient Services was the largest at $32.89M (74.1%), ahead of Pharmaceuticals at $11.51M (25.9%).
Compared with fiscal 2020, Patient Services grew 25.0% to $32.89M and Pharmaceuticals grew 22.4% to $11.51M.
Jrsis Health Care began breaking out Patient Services in fiscal 2020 and Pharmaceuticals in fiscal 2020. Jrsis Health Care stopped reporting Medical Consulting ($8.72M in fiscal 2018), Western Pharmaceuticals ($8.61M in fiscal 2018), Medical Treatment ($8.11M in fiscal 2018) and three others as separate revenue lines.
Medical Treatment was Jrsis Health Care’s largest product and service line in fiscal 2021, bringing in $17.51M of $44.39M (39%).
| Product and Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 |
|---|---|---|---|---|---|
| Patient Services | $17.22M | — | — | — | |
| Patient Services[Member] | — | — | — | — | |
| Medical Treatment | — | — | $12.29M | $17.51M | |
| Patient Services | Medical Treatment | — | $9.94M | — | — | |
| Medical Consulting | — | — | $12.62M | $14.13M | |
| Patient Services | Medical Consulting | — | $9.64M | — | — | |
| Medicin | $11.18M | — | — | — | |
| Medicine | — | — | — | — | |
| Western Pharmaceuticals | — | — | $7.24M | $9.04M | |
| Western Medicine | — | $8.33M | — | — | |
| Herbal Medicine | — | — | $1.30M | $1.51M | |
| Medicine | Herbal Medicine | — | $1.05M | — | — | |
| Others | — | $1.11M | $1.40M | $1.25M | |
| Chinese Medicine | — | — | $864.53K | $956.50K | |
| Medicine | Chinese Medicine | — | $1.40M | — | — | |
| Total | $28.40M | $31.46M | $35.71M | $44.39M |
Jrsis Health Care brought in $44.39M from its six product and service lines in fiscal 2021, the year ended December 31, 2021. That was up 24.3% from $35.71M in fiscal 2020. Medical Treatment was the largest at $17.51M (39.4%), ahead of Medical Consulting at $14.13M (31.8%) and Western Pharmaceuticals at $9.04M (20.4%). The other three lines brought in $3.71M combined.
Compared with fiscal 2020, Medical Treatment grew fastest, up 42.5% to $17.51M, while Others fell the most, down 10.8% to $1.25M.
Jrsis Health Care began breaking out Medical Treatment in fiscal 2020, Medical Consulting in fiscal 2020, Western Pharmaceuticals in fiscal 2020 and Herbal Medicine in fiscal 2020. Jrsis Health Care stopped reporting Patient Services ($17.22M in fiscal 2018), Medicin ($11.18M in fiscal 2018), Patient Services | Medical Treatment ($9.94M in fiscal 2019) and four others as separate lines.
Jrsis Health Care (JRSS) reports its revenue by related party, type, by health care organization revenues and by product and service. In fiscal 2023, Service Rendered Directly To Third Parties was its largest revenue line, bringing in $1.39M (40.2% of the total), followed by Service Rendered To Related Parties at $959.26K (27.7%).
Service Rendered Directly To Third Parties was Jrsis Health Care's largest revenue line in fiscal 2023, bringing in $1.39M, or 40.2% of the $3.46M total across its four revenue lines.
Medical Treatment was Jrsis Health Care's largest product and service line in fiscal 2021, bringing in $17.51M, or 39.4% of the $44.39M total across its six product and service lines.
Patient Services grew faster than Pharmaceuticals in fiscal 2021, up 25.0% from $26.31M to $32.89M. Pharmaceuticals grew 22.4% to $11.51M.
Every figure comes from Jrsis Health Care's annual financial filings, as reported. Each line keeps the name Jrsis Health Care gives it, and years follow its fiscal calendar.
Jrsis Health Care's revenue by related party, type goes back to fiscal 2022, with figures through fiscal 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.